Adam Feuerstein on Muck Rack

Adam Feuerstein Verified

As seen in:  The Street

Sr. Columnist at TheStreet, aka the Col. Jessup of biotech/drug stocks. Data Are. I curse. Said one analyst: The likes of Adam Feuerstein attack viciously.

MannKind (MNKD) Fails Twitter Like It Does Afrezza

thestreet.com — MannKind can't even do Twitter right. The following conversation between MannKind's official Twitter account and a couple of biotech Twitter followers occurred last night, following the company's conference call. It pretty much sums up MannKind's overall cluelessness and explains why the company is on the express train to bankruptcy.

Gilead (GILD): Most Valuable Biotech Asset in Market is Our Own Stock

thestreet.com — Gilead Sciences found a valuable asset to buy: More of its own stock. The Foster City, Calif.-based biotech giant announced a new, $12 billion share repurchase plan on Tuesday night in conjunction with fourth-quarter earnings. Gilead still has $8 billion remaining under an existing stock buyback program, of which $5 billion will be utilized within the next three months.
Feb 03, 2016

$GILD : Most Valuable Biotech Asset in Market is Our Own Stock thestreet.com/story/13445484… But M&A not off table completely.

Axovant (AXON) Sinks on Pfizer (PFE) Alzheimer's Drug Blowup

thestreet.com — The disclosure Tuesday that Pfizer shelved an Alzheimer's drug candidate because of disappointing efficacy is having a negative impact on the market value of Axovant Sciences , which is developing a similar Alzheimer's drug. In an update to its drug research pipeline, Pfizer said a mid-stage study of Alzheimer's drug candidate PF-05212377 was terminated on Oct.

Merck (MRK) Takes on Gilead (GILD) With Sharply Lower Hepatitis C Drug Price

thestreet.com — The list price for Merck's newly approved hepatitis C drug is significantly lower than competing therapies offered by Gilead Sciences and Abbvie , which means a new price war could be heating up. On Thursday night, the U.S. Food and Drug Administration approved Zepatier, a single, daily pill combining two medicines to treat two different forms of hepatitis C.
Jan 29, 2016

$MRK Takes on $GILD $ABBV With Sharply Lower Hepatitis C Drug Price thestreet.com/story/13440730… What Zepatier’s $54K price means, and doesn’t.

Jan 29, 2016

Also $MRK hep C approval and discount on list price may be weighing on both $GILD & $ABBV thestreet.com/story/13440730…

Jan 29, 2016

RT @adamfeuerstein: $MRK Takes on $GILD $ABBV With Sharply Lower Hepatitis C Drug Price thestreet.com/story/13440730… What Zepatier’s $54K price means, and doesn’t.

Celldex (CLDX) Nears Pivotal Decision Point for Brain Tumor Therapy

thestreet.com — A pivotal brain tumor clinical trial involving a cancer immunotherapy from Celldex Therapeutics is approaching a key decision point. As you'd expect, the outcome will have a volatile impact on Celldex's stock price, up or down. Let's take a closer look at the hot issues and burning questions.
Jan 28, 2016

$CLDX nears pivotal decision point for brain tumor therapy thestreet.com/story/13438923… A preview of Rintega ACT IV study in frontline GBM

Jan 28, 2016

RT @adamfeuerstein: $CLDX nears pivotal decision point for brain tumor therapy thestreet.com/story/13438923… A preview of Rintega ACT IV study in frontline GBM

Jan 28, 2016

Celldex Nears Pivotal Decision Point for Brain Tumor Therapy $CLDX via @adamfeuerstein thestreet.com/story/13438923…

Assume No More Biogen (BIIB) Drug Price Hikes? Not so Fast

thestreet.com — The controversy over drug pricing factored into Biogen's revenue guidance for 2016. On a conference call Wednesday, Biogen CFO Paul Clancy said the company's 2016 revenue forecast of $11.1 billion to $11.3 billion assumes no price increases for its key multiple sclerosis drugs -- Tecfidera, Avonex, Tysabri and Plegridy.

Juno (JUNO), Kite (KITE) Valuations at Risk from Simpler T-Cell Cancer Therapy

thestreet.com — Shares of Juno Therapeutics and Kite Pharma are under pressure Tuesday after U.S. government researchers published a study showing that an off-the-shelf, engineered T cell therapy could induce remissions in patients with advanced blood cancers. The new "allogenic" T-cell cancer therapy study is small and far from conclusive but its methods represent a competitive threat to Juno, Kite and Novartis .
Jan 26, 2016

$JUNO $KITE Valuations at Risk from Simpler T-Cell Cancer Therapy —> thestreet.com/story/13436157…

Biotech String: Editas IPO Terms, Rooting for Shkreli in DC

thestreet.com — Some biotech string to start the week. An important IPO test: Editas Medicine updated the terms of its closely watched initial public offering, according to a regulatory filing Monday. The CRISPR gene-editing startup intends to sell 5.9 million shares (excluding a 15% greenshoe) at a price range of $16 to $18 per share.
Jan 25, 2016

Bio-String: Editas IPO, Shkreli vs. Congressional grandstanders, $MNKD mystery partner revealed, $BIIB EPS preview. thestreet.com/story/13434585…

Biotech Stock Mailbag: Snow Stops Sarepta's (SRPT) FDA Show, So What's Next?

thestreet.com — It's Friday. I was hoping you'd be riveted to my live blog of the Sarepta Therapeutics Food and Drug Administration advisory panel meeting, but a few snowflakes in Washington, D.C., forced a postponement. The consolation prize is this Sarepta-themed Biotech Stock Mailbag, so enjoy! Sticking with Sarepta, Billy D.
Jan 22, 2016

Biotech Stock Mailbag: Snow Stops $SRPT FDA Show, so What's Next? -> thestreet.com/story/13432008… The “No Adcomm” consolation prize. :-(

Jan 22, 2016

RT @adamfeuerstein: Biotech Stock Mailbag: Snow Stops $SRPT FDA Show, so What's Next? -> thestreet.com/story/13432008… The “No Adcomm” consolatio…

Alkermes (ALKS) Depression Drug Failure Crimps Future Growth Outlook

thestreet.com — Alkermes said Thursday the experimental drug ALKS 5461 failed to improve depressive symptoms in patients with hard-to-treat depression, based on negative results from two late-stage clinical trials. The bad news caused shares of Alkermes to fall 30% to $42 in early Thursday trading.
Jan 21, 2016

$ALKS Depression Drug Failure Crimps Future Growth Outlook —> thestreet.com/story/13431115…

Jan 21, 2016

RT @adamfeuerstein: $ALKS Depression Drug Failure Crimps Future Growth Outlook —> thestreet.com/story/13431115…

Jan 21, 2016

RT @adamfeuerstein: $ALKS Depression Drug Failure Crimps Future Growth Outlook —> thestreet.com/story/13431115…

More Articles →
Feb 08, 2016

. @Sport234a @sharkbiotech I count 53 biotech/drug stocks down 50% or more YTD (all market caps.) Incredible.

Feb 08, 2016

Like its newly approved drug, $NEOS offering is fast dissolving. twitter.com/TradeHawk/stat…

Feb 08, 2016

@briefsofbrandon I said pre-commercial, not preclinical. Pre-commercial includes late-stage.

Feb 08, 2016

To clarify my prior tweet, Big Pharma skittish to pay big $ for pre-commercial biotech cos., even if YOU think assets are cheaper.

Feb 08, 2016

I heard exactly the opposite from someone who does deals and talks to Big Pharma all the time. twitter.com/CT_Morrison/st…

Feb 08, 2016

@ArmstrongDrew @megtirrell @StephanieSimon_ How many pregnant Spring Breakers are there? Is that a new thing?

Feb 08, 2016

@ggreeneva Giuliani saw Beyonce attacking cops. Everyone else saw Beyonce rescuing the SB halftime show from Coldplay.

Feb 08, 2016

Appears registration statemt required for $AVXL to sell stock via Lincoln Park Cap. has not yet been declared effective by SEC. Been months.


Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.